An observational study in Status Epilepticus and Convulsive Status Epilepticus, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Assiut University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Status epilepticus is a life-threatening neurological emergency characterized by prolonged seizures or multiple seizures occurring without the patient regaining consciousness between episodes. Convulsive status epilepticus is associated with high rates of morbidity and mortality if not promptly recognized and controlled. While prognostic factors have been studied in various populations, data regarding clinical predictors and hospital outcomes in Upper Egypt remain limited.
The purpose of this prospective, hospital-based observational study is to identify the clinical predictors of short-term outcomes among adult patients presenting with convulsive status epilepticus admitted to Assiut University Hospitals.
All eligible participants aged 18 years and older admitted with convulsive status epilepticus will receive standard-of-care medical management according to institutional clinical protocols. Researchers will systematically collect clinical data, including demographic factors, seizure semiology and duration, underlying etiologies, laboratory tests, neuroimaging findings, and electroencephalography (EEG) results.
Participants will be followed throughout their hospital stay to assess functional outcome at discharge using the Modified Rankin Scale (mRS), in-hospital mortality, response to antiseizure treatment, development of refractory or super-refractory status epilepticus, requirement for intensive care unit (ICU) admission or mechanical ventilation, and length of hospital stay.
124 studies on the registry are indexed under Status Epilepticus; 37 are open to participants now.
This study's planned enrollment of 100 is below the median of 156 across 42 observational studies indexed under Status Epilepticus.
Browse Status Epilepticus studies →Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Adult patients presenting with convulsive status epilepticus admitted to the emergency, neurology, or intensive care departments at Assiut University Hospitals. The population includes individuals aged 18 years and older presenting with continuous convulsive seizure activity lasting more than 5 minutes or two or more discrete seizures without full recovery of consciousness between episodes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Adult patients (aged 18 years and older) admitted to Assiut University Hospitals presenting with convulsive status epilepticus, defined as continuous convulsive seizure activity lasting more than 5 minutes or two or more discrete seizures without full recovery of consciousness between episodes. All enrolled participants receive standard-of-care medical management according to institutional guidelines, including first- and second-line antiseizure medications, anesthetic agents, and intensive care or mechanical ventilation when clinically required. Demographic characteristics, clinical features, etiology, laboratory investigations, neuroimaging, electroencephalography (EEG), and treatment responses are prospectively collected throughout hospitalization until discharge to determine clinical predictors of outcome.
Modified Rankin Scale Score
Functional outcome assessed using the Modified Rankin Scale (mRS). The mRS is an ordinal scale ranging from 0 (no symptoms) to 6 (death). Scores 0-2 indicate functional independence, while scores 3-6 indicate functional dependence or death. Higher scores reflect worse clinical outcome.
Time frame: Up to 30 days
No study locations are listed for this record.
Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.
Of 20 observational studies under Status Epilepticus, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 14. This study's planned 12 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.